[Systemic treatment of patients with metastatic neuroendocrine Neoplasia].
| Autor: | Rinke A, Eilsberger F |
|---|---|
| Jazyk: | němčina |
| Zdroj: | Deutsche medizinische Wochenschrift (1946) [Dtsch Med Wochenschr] 2024 Aug; Vol. 149 (15), pp. 879-886. Date of Electronic Publication: 2024 Jul 16. |
| DOI: | 10.1055/a-2173-0588 |
| Abstrakt: | Due to the complexity and heterogeneity of metastatic NEN an interdisciplinary expert team should be involved in an individualized treatment strategy. SSA is the mainstay of antisecretory treatment in most functioning tumors. In antiproliferative intention SSA are first line treatment in receptor positive low proliferative NET. In intestinal metastatic disease PRRT is best established second line treatment. Further options are Everolimus (labeled) and tyrosine kinase inhibitors (off-label). Everolimus is the only approved drug for antiproliferative treatment in patients with metastatic lung NET, whereas in pancreatic NET more therapeutic options are available (SSA, chemotherapy, PRRT, Sunitinib, Everolimus) without a standard of best sequence. In patients with metastatic NEC standard first line treatment (platinum + etoposide) has not changed for decades and new treatment options for this fatal disease are urgently needed. Benefit of immunotherapy is limited to a small subset of patients - new combinations are under investigation. This review summarizes the standard of care, criteria of treatment selection and new developments for systemic therapy in patients with metastatic NEN. Competing Interests: Anja Rinke hat Honorare für Vortragstätigkeit oder Teilnahme an Advisory Boards erhalten von Advanz Pharma, Esteve Pharma GmbH, IPSEN Pharma GmbH, Novartis Radiopharmaceuticals GmbH, Serb Pharma GmbH. (Thieme. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|